Business
Johnson & Johnson deserves more credit for another healthy quarter and strong guidance
The new year has been tough for pharma stocks, including JNJ. But it should not be read as an indictment of the company’s practices.
The new year has been tough for pharma stocks, including JNJ. But it should not be read as an indictment of the company’s practices.